[go: up one dir, main page]

WO2003031435A8 - Pyrazole derivatives as glycine transporter inhibitors - Google Patents

Pyrazole derivatives as glycine transporter inhibitors

Info

Publication number
WO2003031435A8
WO2003031435A8 PCT/EP2002/010172 EP0210172W WO03031435A8 WO 2003031435 A8 WO2003031435 A8 WO 2003031435A8 EP 0210172 W EP0210172 W EP 0210172W WO 03031435 A8 WO03031435 A8 WO 03031435A8
Authority
WO
WIPO (PCT)
Prior art keywords
disease
transporter inhibitors
glycine transporter
pyrazole derivatives
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/010172
Other languages
French (fr)
Other versions
WO2003031435A1 (en
Inventor
Kai Schiemann
Michael Arlt
Dirk Finsinger
Karl-August Ackermann
Wilfried Rautenberg
Joachim Leibrock
Hartmut Greiner
Takahiko Tobe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Merck Patent GmbH
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Yamanouchi Pharmaceutical Co Ltd filed Critical Merck Patent GmbH
Priority to AU2002342675A priority Critical patent/AU2002342675A1/en
Publication of WO2003031435A1 publication Critical patent/WO2003031435A1/en
Publication of WO2003031435A8 publication Critical patent/WO2003031435A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of the formula (I) and salts and solvates thereof, in which X, R?1, R2, R3, R4 and R5¿ are as defined in Claim 1, are suitable as glycine transporter inhibitors and can be used in human and veterinary medicine for the prophylaxis and treatment of schizophrenia, depression, dementia, Parkinson's disease, Alzheimer's disease, Lewy bodies dementia, Huntington's disease, Tourette's syndrome, anxiety, learning and memory restrictions, neurodegenerative disorders and other cognitive impairments, as well as nicotine dependence and pain.
PCT/EP2002/010172 2001-10-06 2002-09-11 Pyrazole derivatives as glycine transporter inhibitors Ceased WO2003031435A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002342675A AU2002342675A1 (en) 2001-10-06 2002-09-11 Pyrazole derivatives as glycine transporter inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10149370A DE10149370A1 (en) 2001-10-06 2001-10-06 New 1-(phenyl or pyridinyl)-1H-pyrazole derivatives, are glycine transporter inhibitors useful e.g. for treating schizophrenia, depression, dementia, neurodegenerative diseases or pain
DE10149370.3 2001-10-06

Publications (2)

Publication Number Publication Date
WO2003031435A1 WO2003031435A1 (en) 2003-04-17
WO2003031435A8 true WO2003031435A8 (en) 2003-05-15

Family

ID=7701652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010172 Ceased WO2003031435A1 (en) 2001-10-06 2002-09-11 Pyrazole derivatives as glycine transporter inhibitors

Country Status (3)

Country Link
AU (1) AU2002342675A1 (en)
DE (1) DE10149370A1 (en)
WO (1) WO2003031435A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275637A1 (en) * 2002-10-24 2004-05-13 Wakamoto Pharmaceutical Co., Ltd. Pyrazole-4-alkanoate derivatives inhibiting cyclooxygenase and 5-lipoxygenase
KR20050096956A (en) 2003-02-07 2005-10-06 다이이찌 세이야꾸 가부시기가이샤 Pyrazole derivative
DE10315572A1 (en) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituted pyrazoles
DE10315573A1 (en) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituted pyrazoles
DE10315571A1 (en) 2003-04-05 2004-10-14 Merck Patent Gmbh pyrazole
DE10315569A1 (en) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituted pyrazole compounds
CA2593274C (en) * 2005-01-14 2013-10-29 N.V. Organon Glycine reuptake inhibitors for treating drug and alcohol dependence
JP5210165B2 (en) 2005-10-05 2013-06-12 バイエル・クロップサイエンス・アーゲー Plants with increased amino sugar content
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
WO2007052615A1 (en) 2005-10-31 2007-05-10 Eisai R & D Management Co., Ltd. Pyridine derivative substituted by heterocycle and fungicide containing the same
JP5229567B2 (en) * 2005-12-30 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション CETP inhibitor
ES2452822T3 (en) * 2006-06-28 2014-04-02 Amgen Inc. Glycine transporter 1 inhibitors
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
KR20100015897A (en) 2007-04-27 2010-02-12 에자이 알앤드디 매니지먼트 가부시키가이샤 Salt of heterocycle-substituted pyridine derivative or crystal thereof
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
CN101784533B (en) 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
MX2010002608A (en) 2007-09-06 2010-06-01 Merck Sharp & Dohme Soluble guanylate cyclase activators.
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
ES2397764T3 (en) 2008-04-01 2013-03-11 Abbott Gmbh & Co. Kg Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
MX2011008952A (en) 2009-02-26 2011-09-27 Merck Sharp & Dohme Soluble guanylate cyclase activators.
AU2011277426B2 (en) 2010-07-15 2015-04-23 Sumitomo Pharma Co., Ltd. Pyrazole compound
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2853254A1 (en) 2011-11-18 2013-05-23 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
CN105339351B (en) 2013-03-14 2018-11-06 Epizyme股份有限公司 Arginine methyltransferase inhibitors and uses thereof
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP2970131B1 (en) 2013-03-14 2017-11-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9346761B2 (en) 2013-03-14 2016-05-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055771A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US11344539B2 (en) 2016-02-19 2022-05-31 National University Corporation Tottori University Therapeutic or prophylactic drug for dementia
ITUA20164199A1 (en) * 2016-06-08 2017-12-08 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro MODULATORS OF SOCE COMPISATIONS AND RELATED USES
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906252A1 (en) * 1979-02-19 1980-08-28 Merck Patent Gmbh PYRAZOLE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
AU2001256769A1 (en) * 2000-05-19 2001-11-26 Merck Patent Gmbh Triazole derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Also Published As

Publication number Publication date
DE10149370A1 (en) 2003-04-10
WO2003031435A1 (en) 2003-04-17
AU2002342675A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
WO2003031435A8 (en) Pyrazole derivatives as glycine transporter inhibitors
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
WO2002098849A3 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
NO20060768L (en) 1- (2-Amino-benzene) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
ATE248837T1 (en) QUINUCLIDINE-ACRYLAMIDE
GEP20105053B (en) Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
SG148846A1 (en) Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimeræs and related neurodegenerative disorders
SE0104332D0 (en) Therapeutic agents
GEP20063958B (en) 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2005018557A3 (en) Substituted pyridinones
YU29102A (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
GEP20125405B (en) Amino-heterocyclic compounds
NO20025517D0 (en) triazole derivatives
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
ATE253918T1 (en) USE OF HYMENIALDISINE AND ITS DERIVATIVES FOR THE PRODUCTION OF THERAPEUTIC AGENTS
WO2005111002A3 (en) Substituted cycloalkyl derivatives for use in the treatment of respiratory diseases
MXPA05014201A (en) Pyrazolo`3,4-b!pyridin-6-ones as gsk-3 inhibitors.
YU4903A (en) N-/5-///5-alkyl-2-oxazolyl-methyl-thio/-2-thiazolyl/ carboxamide inhibitors of cyclin dependent kinases
AU2001241183A1 (en) Amide compounds and use thereof
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
MXPA05013628A (en) Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors.
TW200502234A (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
DE60108626D1 (en) USE OF 5-THIO, SULFINYL AND SULFONYLPYRAZOLO 3,4-B] PYRIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP